NSE: SUPRIYA | BSE: 543434

Mid-range Performer

Download real time

638.10 14.80 (2.37%)

93.36% Gain from 52W Low

357.2K NSE+BSE Volume

NSE 08 May, 2025 3:31 PM (IST)

5,135.6

Market Cap

Above industry Median

1.6

Beta 1Year

Very High Volatility

Supriya Lifescience Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUPRIYA, BSE:543434 Supriya Lifescience Ltd.

Supriya Lifescience Ltd.

18 Aug 2022

638.10

2.37%

Improving capabilities towards sustainable growth.

Accumulate: Supriya Lifescience Ltd.

KRChoksey

During Q1FY23, Supriya Lifescience Ltd (SLL) reported Revenue of INR 1,037 Mn (+31.43% YoY / -43.98% QoQ).

Number of FII/FPI investors increased from 85 to 98 in Mar 2025 qtr.

Supriya Lifescience Ltd.

16 Dec 2021

638.10

2.37%

SUPRIYA LIFESCIENCES LTD.

IPO Note: Supriya Lifescience Ltd.

Hem Securities

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. As of October 31, 2021, company have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic,...

Number of FII/FPI investors increased from 85 to 98 in Mar 2025 qtr.

Supriya Lifescience Ltd.

16 Dec 2021

638.10

2.37%

Supriya Lifescience : IPO

IPO Note: Supriya Lifescience Ltd.

ICICI Securities Limited

Supriya has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between FY17 and FY21. SLL is among the largest exporters of Salbutamol Sulphate in India contributing to...

Supriya Lifescience Ltd. is trading below its 30 day SMA of 706.7

Supriya Lifescience Ltd.

15 Dec 2021

638.10

2.37%

Supriya Lifescience Ltd

IPO Subscribe: Supriya Lifescience Ltd.

Angel Broking

Supriya Lifescience Limited was incorporated in March 2008 by Satish Waman Wagh. Company is one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients (APIs). Supriya Lifescience Limited focus on research and development along with this company focus is on diverse therapeutic areas and niche products. Company has niche product offerings of 38

Number of FII/FPI investors increased from 85 to 98 in Mar 2025 qtr.

Supriya Lifescience Ltd.

15 Dec 2021

638.10

2.37%

SUPRIYA LIFESCIENCE LTD.

IPO Note: Supriya Lifescience Ltd.

Ventura

IPO NOTE

Supriya Lifescience Ltd. is trading above its 200 day SMA of 637.6

Supriya Lifescience Ltd.

15 Dec 2021

638.10

2.37%

Supriya Lifescience Ltd. IPO Note

IPO Note: Supriya Lifescience Ltd.

Ashika Research

Public issue of 2,55,47,445 Equity shares of Face value Total Public 2 each, (Comprising of fresh issue of 72,99,270 Equity Shares* (Rs. 200 cr.) and Offer for Sale of 1,82,48,175 Equity Shares* (Rs. 500 cr.) by Selling Shareholder)....

Supriya Lifescience Ltd. has gained 63.45% in the last 1 Year

VOTE: Is Supriya Lifescience Ltd. worth buying?

97 Votes:

Buy 85.57%

Sell 7.22%

Hold 7.22%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf